Glenview Capital (Larry Robbins and Mark Horowitz) discloses updated portfolio positions in 13F filing: New DNA ARRY EXAS W CAR AVGO positions, Increased ALIT TEVA ESI CTVA positions
Highlights from Q1 2024 filing as compared to Q4 2023 (all amounts are approximate):
- New positions in: DNA (24 mln shares), ARRY (2.2 mln), EXAS (0.23 mln), W (0.22 mln), CAR (0.18 mln), AVGO (0.02 mln)
- Increased positions in: ALIT (to 28.32 mln shares from 18.2 mln shares), TEVA (to 7.5 mln from 1.6 mln), ESI (to 8.36 mln from 3.76 mln), CTVA (to 6.79 mln from 4.7 mln), MRVL (to 1.37 mln from 0.18 mln), CVS (to 1.7 mln from 0.75 mln), USFD (to 2.52 mln from 1.75 mln), KNX (to 1.33 mln from 0.86 mln)
- Maintained positions in: CLVT (24.65 mln shares)
- Closed positions in: INTC (from 0.34 mln shares), CAH (from 0.2 mln), CHTR (from 0.12 mln)
- Decreased positions in: BKD (to 14.44 mln shares from 16.94 mln shares), THC (to 6.33 mln from 7.74 mln), VTRS (to 5.14 mln from 6.07 mln), UBER (to 1.13 mln from 1.96 mln), VVV (to 1.63 mln from 2.32 mln), CI (to 1.47 mln from 2.14 mln), MYGN (to 4.94 mln from 5.28 mln), AMZN (to 0.4 mln from 0.69 mln), DNB (to 3.61 mln from 3.86 mln), DXC (to 12.78 mln from 13.01 mln), FI (to 0.8 mln from 0.94 mln), EXPE (to 0.61 mln from 0.7 mln), HCA (to 0.2 mln from 0.25 mln), META (to 0.11 mln from 0.16 mln), MCK (to 0.29 mln from 0.33 mln